BIOCHINA2026（第十一届）易贸生物产业展览将于3月12-14日在苏州盛大举行！现场将汇聚30000名生物产业同仁，数千名投资人、Biotech创始人、Pharma C-level及BD负责人齐聚一堂，高效对接项目、洽谈合作。

BIOCHINA2026期间，BiOFUNDING易企融资路演设置了韩国项目路演专场，深度聚焦生物医药领域前沿趋势与核心发展方向，为优质项目与资本精准对接搭建专业平台。

目前，韩国项目路演征集了一批具有核心技术、清晰商业模式与巨大市场潜力的优质项目，参与路演可在此精准对接资源，挖掘中韩产业融合下的投融资机遇。

项目亮点一览

项目名称/Project Name：

Anti-B7-H3 ADC (ITC-6146RO)

项目亮点/Project Highlights

Developed the Proprietary OHPAS™ Cleavable Linker Platform to achieve enhanced plasma stability, controlled intracellular release, and improved therapeutic index.

Developed differentiated payload platform based on camptothecin derivatives, Nexatecan and iso-Nexatecan as well as next-generation cytotoxic payloads optimized for ADC applications.

Holds a robust global IP portfolio spanning linker chemistry, payload derivatives, and ADC constructs.

Recently achieved phase 1 clinical trial approvals for its lead ADC program against clinically validated oncology targets, B7-H3.

Actively pursues strategic collaborations and licensing opportunities with global biopharmaceutical partners to maximize the value of its platform technologies.

项目名称/Project Name：

Engineered Exosome Platform for Targeted Anti-Inflammatory Therapy

项目亮点/Project Highlights

This project is based on a proprietary exosome platform designed for targeted intracellular delivery of anti-inflammatory biologics across multiple therapeutic areas. The lead program, representing the first clinical translation of the platform, has demonstrated robust, reproducible efficacy in diverse in vitro and in vivo inflammatory disease models, with favorable safety and tolerability profiles.

Compared to conventional delivery systems, the platform offers differentiated advantages in tissue targeting, biological stability, and intracellular delivery efficiency. Its modular design enables efficient cargo loading and selective delivery, allowing precise modulation of disease-relevant inflammatory pathways in renal, autoimmune, ophthalmic, CNS, and women’s health indications.

Preclinical studies have confirmed favorable biodistribution and pharmacological profiles, supporting broad therapeutic applicability and expansion potential across indications. The program is currently progressing toward IND-enabling studies, supported by a defined regulatory strategy and a scalable, GMP-compatible manufacturing process.

This opportunity provides partners with early access to a differentiated exosome-based delivery platform with strong intellectual property protection, multi-indication pipeline potential, and flexible collaboration structures, including licensing, co-development, and regional commercialization.

项目名称/Project Name：

Lasmotinib (PHI-101)

项目亮点/Project Highlights

This project is a next-generation FLT3 inhibitor being developed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). Lasmotinib demonstrates broad inhibitory activity against key FLT3 resistance mutations, including FLT3-ITD, F691L, D835Y, and N676K, which are not adequately addressed by currently approved FLT3 inhibitors such as gilteritinib, midostaurin, or quizartinib.

In a Phase 1 clinical study in patients with R/R AML, Lasmotinib was generally well tolerated and showed a favorable safety profile. Encouraging clinical activity was observed, with composite complete remission (CRc) rates of 50% and an overall response rate (ORR) of 67% at the 160 mg dose level. Clinical responses were also observed in patients previously treated with FLT3 inhibitors, including gilteritinib.

Pharmacokinetic and pharmacodynamic analyses indicate strong exposure and potency against FLT3-ITD and F691L mutations, with a shorter half-life and higher exposure compared to gilteritinib, supporting potential use in post-gilteritinib settings and combination regimens.

The program is ready for global Phase 2 development and is positioned for both monotherapy in R/R AML and expansion into front-line combination settings. addressing a growing AML market driven by FLT3-targeted therapies.

项目名称/Project Name：

NuGel

项目亮点/Project Highlights

Shaperon’s core pipeline is based on novel small-molecule GPCR19 positive allosteric modulators (PAMs). Unlike earlier GPCR19-targeting approaches that failed due to mixed orthosteric–allosteric binding profiles and limited selectivity, Shaperon’s compounds selectively bind to a distinct allosteric site on GPCR19. This selective engagement avoids orthosteric receptor–related safety issues reported with prior GPCR19 agonists, including gallbladder filling and cardiotoxicity.

Through allosteric modulation of GPCR19 signaling, Shaperon’s PAMs suppress various inflammatory cytokine release by regulating both the priming and activation phases of inflammasome pathway. This dual-phase regulation differentiates the mechanism from conventional inflammasome-targeting therapies, which typically inhibit only the activation phase.

NuGel is a first-in-class topical GPCR19 positive allosteric modulator developed for the treatment of mild-to-moderate atopic dermatitis. In a US-based Phase 2b clinical study, NuGel demonstrated improvements in Eczema Area and Severity Index (EASI) scores and Investigator's Global Assessment (IGA) treatment success. Pharmacokinetic and safety evaluations showed minimal systemic exposure and no treatment-related serious adverse events, supporting advancement to Phase 2b Part 2, which is currently ongoing.

项目名称/Project Name：

AST-001

项目亮点/Project Highlights

AST-001 is the only therapeutic candidate worldwide to have completed Phase 3 clinical trials targeting the core symptoms of autism spectrum disorder (ASD), differentiating it from existing treatments focused on associated symptoms (irritability/aggression). Leveraging its advanced development status, marketing authorization application was submitted in June 2025 to the Korea MFDS, with regulatory approval and launch targeted within 2026 in Korea. Global expansion is underway, including a completed U.S. FDA Pre-IND meeting and on-going preparation for China NMPA pre-IND submission.

项目名称/Project Name：

Alzheimer’s drug development using a TRPML1 agonist

项目亮点/Project Highlights

Our program focuses on developing a first-in-class, orally available controlled TRPML1 agonist for Alzheimer’s and Parkinson’s disease. TRPML1 is a key lysosomal ion channel that regulates intracellular waste clearance, and impaired TRPML1 signaling is closely associated with neurodegenerative pathology. Through our proprietary lysosomal patch-clamp electrophysiology platform, we have discovered small molecules that restore low TRPML1 activity in disease conditions while maintaining a controlled activation profile suitable for chronic dosing.

Our lead candidate, 3BT-1-115, induces low-level but therapeutically effective TRPML1 activation, promoting TFEB pathway engagement, enhanced autophagy–lysosome function, and the clearance of pathological proteins including Aβ, tau, and α-synuclein. In multiple AD and PD animal models, 3BT-1-115 demonstrates significant reductions in toxic protein burden with once-daily oral administration, supporting its potential as a disease-modifying therapy.

We are expanding this platform into additional lysosomal ion channel targets and advancing toward IND-enabling studies. Threebrooks Therapeutics is actively seeking global partners for co-development and licensing to accelerate the delivery of next-generation neurodegenerative therapeutics.

韩国项目专场路演

已报名投资机构高层（部分）

Pharma参会名单（部分）

目前，BIOCHINA2026路演席位仅剩3席！率先报名并完成付费的项目，可优先锁定大会首日黄金路演时段，第一时间聚焦顶级投资人与合作伙伴的目光，速来抢占先机！